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Hepatic secretion of VLDLs is an important determinant 
of lipidemia (1–3). Variations can result from a combina-
tion of changes in the number of particles (each contain-
ing a single molecule of apoB, a large amphipathic protein) 
and the lipid content [especially triglyceride (TAG)] of 
each particle (4). The mechanisms by which VLDL parti-
cles are assembled in the lumen of the endoplasmic reticu-
lum (ER) of hepatocytes is mostly well understood (3, 5), 
but there are still aspects that require further insight. TAG 
is synthesized within the ER membrane and originates be-
tween the two leaflets of the membrane (6). A minority of 
this TAG is incorporated into primordial lipoprotein par-
ticles by association with apoB during the protein’s cotrans-
lational insertion through the ER membrane, resulting 
in lipid-poor apoB-containing nascent particles being di-
rected toward the ER lumen (7).
The rest of the nascent TAG is incorporated into cyto-
solic lipid droplets (LDs), which bud from the ER and are 
surrounded by phospholipid monolayer partly derived 
from the cytosolic leaflet of the ER (6). A complex of pro-
teins appears to link the LD to the ER, facilitating synthesis 
and transfer of TAG to the LD (8). Although it is possible 
that some non-apoB-associated TAG enters the ER lumen 
at the time of synthesis, it is generally accepted that it is the 
pool of TAG within the cytosolic LDs that is the major 
source (9) of TAG for the enlargement [through a second 
lipidation step (10)] of the primordial, lipid-poor lipopro-
tein particles into the secretion-competent fully lipidated 
VLDL particles that are formed at the junction between the 
ER and the Golgi prior to secretion (10). But, in order for 
the cytosolic LD-TAG to be incorporated into VLDL-TAG, 
it needs to be hydrolyzed (11) [mostly to diglyceride, diac-
ylglycerol (DAG) (12, 13)] and resynthesized at a site 
within the ER membrane that directs it toward the lumen 
and results in the formation of the non-apoB-associated 
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TAG-containing LD within the lumen (7, 14, 15). Compo-
sitional studies of the luminal LDs showed that they have a 
distinct proteome of their delimiting membrane from that 
of cytosolic LDs (16). The use of TAG from ER-luminal 
LDs to lipidate the nascent lipoprotein particles results in 
the formation of fully lipidated, large VLDL particles, which 
gain other lipid and protein components in the process (10).
Therefore, the pathway through which cytosolic TAG 
acts as a precursor for the second-step lipidation of VLDLs 
within the ER lumen is important, in that it determines the 
availability of TAG for enlargement of VLDLs and, conse-
quently, the ultimate size of the VLDL particles secreted. 
Larger particles (termed VLDL1) that are secreted under 
conditions of increased hepatic lipogenesis, hyperglyce-
mia, and hyperinsuinaemia [e.g., T2D (2)] may be more 
proatherogenic due to their enhanced susceptibility to li-
polysis by lipoprotein lipase in peripheral vasculature; their 
increased residence time in the plasma results in more 
highly modified, atherogenic, small dense LDL (17). How-
ever, TAG is not an easily membrane-permeant molecular 
species, and in spite of the demonstration that CideB may 
facilitate LD interaction with the ER (18), the known re-
quirement for cytosolic TAG hydrolysis prior to its utiliza-
tion for lipidation of VLDLs (see above) argues against the 
use of TAG molecules being transferred intact across the 
ER bilayer membrane.
We previously described a mechanism for the effective 
transfer of glycerides from cytosolic TAG into the ER lu-
men. This involves the hydrolysis of TAG of cytosolic LDs 
primarily to DAG and monoglyceride (12, 13, 19) and the 
transfer of DAG [a highly membrane-permeant molecule 
(20)] across the ER membrane. This necessitates the resyn-
thesis of TAG on the luminal aspect of the membrane (21). 
In addition to the presence in the ER of proteins that facili-
tate the provision of acyl-CoA substrates at the luminal as-
pect of the ER (22), central to this mechanism is the 
bimodal distribution on either aspect of the ER membrane 
of the activity of diacylglycerol acyltransferase 1 (DGAT1) 
activity (23). DGAT1 appears to belong to a group of oligo-
meric membrane proteins that have bimodal orientations 
within the membranes in which they reside (24). The cyto-
sol-facing subpopulation of DGAT1 enzyme appears to 
catalyze primarily the esterification of DAG with preformed 
FAs derived either endogenously through lipolysis of cyto-
solic LD-TAG or from the circulation (23, 25), whereas the 
lumen-facing DGAT1 is proposed to be central to the for-
mation of the apoB-independent ER luminal LD, whose 
content is used to lipidate the nascent lipoprotein particle 
to form VLDLs (15, 23). By contrast, the other protein with 
major DGAT activity, DGAT2, is distributed in locations 
(including the cytosolic LDs) with its active site exclusively 
orientated toward the cytosolic compartment (26, 27). It 
has also been shown to be specialized for the esterification 
of nascent DAG and de novo synthesized FAs in mouse 
liver (28), HepG2 cells (25), and mouse brown adipocytes 
(29). Similarly, DGAT2 inhibition does not affect esterifica-
tion of external oleate to TAG in the heart (30).
Therefore, we hypothesized that mice lacking DGAT1 
specifically in hepatocytes (DGAT1-LKO mice) would be 
unable to form non-apoB-associated ER luminal LDs; this 
would impair the ability of the liver to form normal-sized 
VLDL particles, as the absence of intraluminal TAG synthe-
sis would diminish the availability of non-apoB-associated 
TAG for second-step lipidation of nascent lipoprotein par-
ticles. Therefore, in this study we have examined the effect 
of hepatocyte DGAT1 deficiency on VLDL size, and TAG 
and apoB content, and find that, as would be predicted from 
the proposed role for the bimodal distribution of DGAT1 
activity across the ER membrane, TAG lipidation of VLDL 
particles is markedly diminished in DGAT1-LKO mice.
MATERIALS AND METHODS
Materials
A TAG assay kit was purchased from Cayman Chemicals (Ann 
Arbor, MI). The ApoB ELISA kit was from LifeSpan Bioscience 
(Nottingham, UK). The RNeasy Mini kit was bought from Qiagen 
(Manchester, UK). [1-14C]-oleoyl-CoA (specific activity 60 mCi/
mmol) was purchased from PerkinElmer (Coventry, UK). A cho-
lesterol assay kit, Triton WR1339, tetrahydrolipstatin (THL), 
DGAT1 inhibitor T863, and all primers were purchased from 
Sigma-Aldrich (Irvine, UK). DGAT2 inhibitor (iJ) was prepared 
by Tocris Bioscience (Abingdon, UK). Heparinized syringes were 
from Abaxis UK Ltd. (York, UK).
Animals
All procedures were performed in compliance with the regula-
tions of the local ethics committee of the University of Warwick 
and licensed under Home Office regulations in the United King-
dom. To generate DGAT1-LKO mice, Alb.Cre and dgat1.lox mice 
were purchased as single strains from Jackson Laboratories 
(through Charles River, Margate, UK) to establish a double-trans-
genic colony. Original crossing of dgat1 (homozygous) and Alb.
Cre (heterozygous) produced double-transgenic offspring (dgat 1 
heterozygotes/Alb.Cre heterozygotes and WT). Once a sufficient 
number of mice were of the right age, sex, and genotype, they 
were then crossed to produce dgat1.lox (homozygotes)/Alb.cre 
(heterozygote and WT). The Alb.Cre WT littermates were used as 
controls. Only male mice were used.
Methods
Triglyceride assay. TAGs were measured in plasma samples, 
whole liver extracts, and isolated microsomes obtained from fed 
or fasted mice using a TAG assay kit according to the supplier’s 
protocol. Blood was collected from mice by cardiac puncture us-
ing heparinized syringes and centrifuged at 1,000 g for 5 min to yield 
plasma, which was assayed for TAG. Samples of livers (350 mg) 
or microsomal pellets (20 mg) were homogenized on ice in the 
NP40 substitute assay reagent of the assay kit and centrifuged at 
10,000 g for 10 min at 4°C. The supernatant was removed and 
used for TAG measurement.
Cholesterol assay. Total cholesterol and cholesteryl esters were 
measured by a colorimetric method (570 nm) using a cholesterol 
quantification kit (Sigma) according to the supplier’s instruc-
tions. Blood was collected from mice by cardiac puncture using 
heparinized syringes and centrifuged at 1,000 g for 5 min to yield 
plasma, which was assayed for cholesterol assay.
ApoB measurement. ApoB was measured in mouse plasma (1 h 
after injection of Triton WR1339) using the ApoB Elisa kit for 
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DGAT1 determines VLDL size but not particle number 113
mouse ApoB (LifeSpan Bioscience) according to the supplier’s 
instructions. ApoB secretion rates by HepG2 cells were quantified 
using the ELISA kit for human ApoB (Mabtech, 2Bscientifc, 
United Kingdom).
DGAT activity assays. DGAT activity was measured in liver ex-
tracts by quantifying the incorporation of [1-14C]-oleoyl-CoA into 
[14C] TAG in the presence of the second substrate 1,2-dioleoylg-
lycerol as described previously (23). Frozen liver samples (200 
mg) were thawed and homogenized on ice in 250 mM sucrose, 50 
mM Tris, and 1 mM EDTA, pH 7.2. Supernatant was collected af-
ter centrifugation at 1,000 g for 10 min at 4°C and incubated on 
ice for 30 min either with carrier DMSO or with the DGAT 1 in-
hibitor [T863; 10 µM final concentration in DMSO)], DGAT2 in-
hibitor (iJ; 50 µM in DMSO) or with both inhibitors. After this 
incubation period, the aliquots (50 µl) were assayed for DGAT 
activity. The final assay medium contained 50 M [1-14C] oleoyl-
CoA (2.2 × 104 dpm/nmol), 500 M 1,2 dioleoylglycerol dis-
solved in ethanol (final concentration of ethanol 0.25%), 2.5 mg/
ml BSA, and 0.6% DMSO in 125 mM Tris-HCl buffer (adjusted to 
pH 7.4 using KOH at 37°C) containing 10 mM MgCl2 and 250 
mM sucrose. The reaction was terminated after 10 min using chlo-
roform/methanol (2:1, v/v). The chloroform layer was dried un-
der a stream of nitrogen gas and resolubilized in chloroform (200 
l); the entire chloroform fraction was loaded onto a TLC plate 
coated with Silica Gel 60; and the lipid radioactive products were 
separated using hexane/diethyl ether/formic acid (70:30:1, 
v/v/v) as the mobile phase. A triglyceride standard (tripalmitin, 
10 nmol) was used to identify the position of the triglyceride band 
after lipid separation. Lipid bands were visualized using iodine 
vapor. The radioactivity of each band was quantified after scrap-
ing into scintillation vials and quantifying the 14C radioactivity us-
ing a scintillation counter.
Real-time PCR quantitation of mRNA expression. Total RNA was 
extracted from livers using the RNeasy Mini Kit (Qiagen) accord-
ing to the manufacturer’s instructions. cDNA was prepared using 
reverse transcription. Briefly, RNA (1 g) was mixed with oligodT 
(1 µl) in a final volume of 12 µl of RNase-free water. Samples were 
heated at 70°C for 5 min before chilling on ice. Subsequently, 8 µl 
of mixture containing RNase inhibitor (10 U/µl), dNTPs (10 
mM), 5× reaction buffer, Bioscript reverse transcriptase, and 
RNase-free water was added to each sample. Samples were heated 
at 40°C for 60 min, and the reaction was stopped by heating to 
70°C for 10 min. cDNA formed was mixed with 180 µl of nuclease-
free water, stored at 20°C, and thawed once before quantifica-
tion. Reverse transcription assay (RT-PCR) was performed using 
SYBR green dye, and expression for all the samples (n  3) was 
calculated by using the DCt method, incorporating the efficien-
cies of each primer pair. The variances of input cDNA were nor-
malized against the levels of two housekeeping genes, L19 and 
B-actin. Melting curve analysis confirmed amplification specificity. 
Sequences of the primers used for each gene are given in Table 1.
Measurement of VLDL particle size using dynamic light scattering. Ty-
loxapol (Triton WR1339, 200 µl; 2.5% in 0.9% PBS, 10 g of body 
weight) was injected 1 h before blood sampling to increase the 
VLDL fraction. Mice were terminally anesthetized using pentobar-
bitone, and blood was collected in tubes containing 5 l of a saline 
solution of THL (200 µM final concentration). Blood from up to 
three mice was pooled to obtain a sufficient amount of purified 
VLDL fraction. The pooled blood was centrifuged at 1,000 g for 
5 min. The supernatant was collected, aliquots were overlaid with 
KBr solution (density 1.008), and the VLDL fraction was purified by 
differential centrifugation at 27,000 g for 14 h at 12°C. The surface 
fraction containing the VLDL fraction was collected (200 µl) and 
used for dynamic light scattering (DLS) measurements immedi-
ately, without dialysis. Samples of the KBr medium were used as 
controls. DLS data were obtained using a Malvern Zetasizer Nano S 
633 nm (Malvern, UK). Measurements of the particle size of VLDL 
fractions were obtained using 1.0 cm path length disposable micro-
UV cuvettes (Brand, Germany). Samples were equilibrated at 37°C 
for 40 min prior to measurements, to stabilize Brownian activity and 
ensure reliable size determination, before aliquots (50 l) were 
added to cuvettes. Measurements were performed at 37°C with 
300 s equilibration time. Automated instrument parameters were 
used. Each measurement was repeated a minimum of seven times. 
The sample data obtained were normalized for intensity; means 
and SEMs were calculated. Viscosity (0.6864 cP at 37°C) and refrac-
tive index (1.330 at 37°C) of KBr solution were used. The refractive 
index of 1.450 was used for lipoprotein fractions. To calibrate the 
size measurement using these parameters, sample solutions were 
spiked using a 100 ± 3 nm National Institute of Standards and Tech-
nology traceable size standard (NanosphereTM, ThermoScientific).
HepG2 cell culture. HepG2 cells were purchased from the JCRB 
cell bank. They were cultured in RPMI 1640 medium supple-
mented with 10% FBS, 1% penicillin/streptomycin, 10 mM HEPES, 
and 2 mM l-glutamine at 37°C. Cells were subcultured every 5–6 
days, just prior to reaching about 80–90% confluency, into fresh 
vented culture flasks or into 6-well plates for experimental work. 
Unless specified otherwise, all experiments were performed in 
phenol-free medium with 10% FBS, 1% penicillin/streptomycin, 
10 mM HEPES, 2 mM l-glutamine, and 0.75 mM oleate with 25% 
BSA. Cells treated with either iDGAT1 (T863; 10 µM) or iDGAT2 
(iJ; 5 µM) and apoB secretion into the medium quantified after 4 
h at 37°C using a human ApoB ELISA kit (see Materials). Initial 
experiments ascertained that secretion was linear up to this time 
point. ApoB levels were measured in the medium according to 
the manufacturer’s protocol. Levels were normalized to protein 
concentrations.
Preparation of microsomal fraction from mouse livers. The livers 
were homogenized using a Teflon-glass homogenizer in 10 vol of 
ice-cold medium containing 250 mM sucrose, 1 mM EGTA, and 
10 mM Tris (pH 7.2). The homogenates were centrifuged for 10 
min at 1,000 g. The supernatant was centrifuged twice for 20 min 
TABLE 1. Sequences of primers used for quantification of mRNA expression of different genes in mouse livers
Gene Forward Reverse
mDGAT1 TTCCGCCTCTGGGCATT AGAATCGGCCCACAATCCA
mDGAT2 AGTGGCAATGCTATCATCATCGT TCTTCTGGACCCATCGGCCCCAGGA
mFAS TGCGGAAACTTCAGGAAATGT AGAGACGTGTCACTCCTGGACTT
mACC1 TGTCCACCCAAGCATTTCTTC CATCCAACACCAGTTCAGTATACGT
mGPAT4 TGCCAAATGGGAGGTTTAAG GCCACCATTTCTTGGTCTGT
mGPAT1 GTCCTGCGCTATCATGTCCA GGATTCCCTGCCTGTGTCTG
mSCD1 CATCGCCTGCTCTACCCTTT GAACTGCGCTTGGAAACCTG
mActin B TTGCTGACAGGATGCAGAAG CCACCGATCCACACAGACTA
mL19 GGAAAAAGAAGGTCTGGTTGGA TGATCTGCTGACGGGAGTTG
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at 10,000 g, and subsequently at 76,000 g for 4 h. The purified 
microsomal fraction was recovered from the high-speed pellet.
Electron microscopy. Tissue sampling and fixation was per-
formed as described in ref. 31. Images were obtained using a Jeol 
2100Plus microscope equipped with a Gatan OneView Camera.
Statistical analyses. Differences between means for indepen-
dent groups of data were analyzed by Student’s t-test or paired 
Student’s t-test, as indicated. Nonparametric data analysis was per-
formed using the Mann-Whitney U test.
RESULTS
Liver and plasma parameters of DGAT1-LKO mice
The hepatocyte-specific loss of DGAT1 expression re-
sulted in virtual elimination of the mRNA expression for 
the dgat1 gene (Fig. 1A). There was a small increase in the 
mRNA expression for DGAT2, indicating that DGAT2 ex-
pression was not induced significantly to compensate for 
the absence of DGAT1. The loss of DGAT1 expression was 
accompanied by the loss of approximately half the DGAT 
activity in the liver (Fig. 1B). The difference in overall he-
patic DGAT activity in DGAT1-LKO mice was comparable 
to the degree of inhibition of overall DGAT activity by a 
specific DGAT1 inhibitor (T863) (Fig. 1B). This was consis-
tent with the observation that in DGAT1-LKO livers, the 
overall activity of DGAT was unaffected by T863, whereas it 
was markedly inhibited by compound iJ (29), which is a 
specific inhibitor of DGAT2. These observations confirmed 
that the Cre-Lox strategy (see Methods) used to specifically 
knock down dgat1 gene expression in the hepatocytes of 
DGAT1-LKO mice had effectively resulted in the total ab-
sence of the functional enzyme from the hepatocytes. Mi-
nor residual DGAT activity in the livers of both WT and 
DGAT1-LKO mice after combined exposure to DGAT1 
and DGAT2 inhibitors indicates that some DGAT activity is 
attributable to other enzymes able to esterify DAG to TAG 
in the in vitro assay and/or to DGAT1 activity in other cell 
types within the liver.
Neither the TAG content of the liver nor the plasma con-
centration of TAG were affected relative to WT control val-
ues in DGAT1-LKO mice in the fed state (Fig. 2). Although 
there was a tendency for TAG content of liver to increase 
after 6 h fasting, particularly in WT animals, the differences 
were not statistically significantly higher than the TAG con-
tent of fed control mice.
Changes in hepatic lipogenic enzyme mRNA expression in 
DGAT1-LKO mice
We quantified the mRNAs for several lipogenic genes in 
the livers of fed mice to ascertain whether the absence of 
DGAT1 from hepatocytes was likely to have altered the lipo-
genic potential of hepatocytes in DGAT1-LKO mice (Fig. 3). 
Fig. 2. Triglyceride concentrations in liver and plasma of WT and 
DGAT1-LKO mice. WT (black bars) or DGAT1-LKO (gray bars) 
mice were used either in the fed state (l h into the 12 h light period) 
or in the fasted state, 6 h into the light period of a 12 h light/12 h 
dark diurnal cycle. Blood was obtained, using heparinized syringes, 
by cardiac puncture of anesthetized animals, and liver samples were 
obtained and frozen immediately. Plasma was prepared from the 
blood samples by centrifugation at 10,000 g for 5 min. Values for 
liver content (A) and plasma concentration (B) are means (± SEM) 
for five separate determinations on separate mice. The increase 
in liver TAG content after 6 h fasting did not reach statistical 
significance.
Fig. 1. Effect of the conditional knockout of the dgat1 gene in he-
patocytes (DGAT1-LKO) on mRNA expressions of the dgat1 and 
dgat2 genes (A) and hepatic activity of DGAT in the presence of spe-
cific DGAT1 or DGAT2 inhibitors (inhib) (B). A: The loss of DGAT1 
expression in the liver of DGAT1-LKO mice (KO) was verified. This 
was accompanied by a modest, but significant, increase in the mRNA 
expression of DGAT2. Values, in arbitrary units (A.U.), for each 
gene are expressed relative to the geomean of mRNA expression of 
two housekeeping genes, L19 and Actin B, for five separate liver 
RNA preparations. B: DGAT activities were measured in liver whole 
homogenates of frozen liver samples in the absence or presence of 
specific inhibitors of DGAT1 or DGAT2 or a combination of the two 
(see Methods). The control DGAT activity in liver of WT mice was 
0.98 µmol/min/g liver at 37°C. *Statistically different values (P < 0.02).
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DGAT1 determines VLDL size but not particle number 115
With one exception (GPAT1), none of the lipogenic genes 
tested showed any increase in mRNA expression. The 
2-fold increase in GPAT1 mRNA may indicate that, in the 
absence of DGAT1, a SREBP1c-independent response (32) 
by the liver may occur to increase the esterification of newly 
synthesized FAs. GPAT1 is localized in the mitochondrial 
outer membrane (33), where it competes for acyl-CoA with 
carnitine palmitoyltransferase 1, thus attenuating the entry 
of FAs into the mitochondrial matrix for -oxidation (32). 
Like DGAT2 (15, 25), GPAT1 is specialized for the esterifi-
cation of de novo synthesized FAs (34), which are the pre-
ferred substrates for DGAT2 in mouse liver (28). Although 
of interest, a study of the implications of these changes for 
the partitioning of hepatic FAs between esterification and 
oxidation was outside the scope of the present study.
VLDL composition in DGAT1-LKO mice
The levels of VLDLs were raised by treatment of the mice 
with Triton-WR1339 (Tyloxapol) 1 h before blood sam-
pling to enable more accurate analyses (see Methods). Ini-
tially, the choice of 6 h fasting was made to avoid the 
interference from chylomicron content of TAG and apoB, 
but also to prevent significant mobilization of FAs from adi-
pose tissue, and a consequent increase in hepatic TAG con-
tent, which occurs with longer duration of fasting both in 
control and DGAT1-deficient mice (35). This minimized 
the possibility that the composition of VLDLs would be in-
fluenced directly by the TAG availability within the liver 
(9). The data in Fig. 2 show that the contents of TAG in 
liver and plasma were not different between control and 
DGAT1-LKO mice after 6 h fasting. However, after 16 h 
fasting, plasma TAG was 40% lower in DGAT1-LKO mice 
(Fig. 4A); by contrast, there was no significant change in 
the concentration of apoB in the plasma; indeed, there 
tended to be an increase (Fig. 4B). These combined effects 
resulted in a significant 55% decrease in the TAG/apoB 
ratio in the plasma of DGAT1-LKO mice after 16 h fasting 
(Fig. 4C). There were no changes in either cholesterol or 
cholesteryl ester concentrations in the plasma (not shown). 
The decrease in TAG/apoB ratio suggested that there was 
a major decrease in the size of individual VLDL particles. 
Therefore, we decided to test this inference directly.
Sizing of VLDL particles
Using DLS (see Methods), we measured directly the 
size of VLDL particles isolated from DGAT1-LKO and 
WT mice. Figure 5 shows that there was a statistically sig-
nificant decrease (20%) in the diameter of VLDL parti-
cles in DGAT1-LKO mice. Assuming that VLDL particles 
behave like spheres, this decrease in diameter is equiva-
lent to a 45% decrease in particle volume, which is con-
sistent with the magnitude of the decrease in TAG/apoB 
ratio observed above (Fig. 4C). Therefore, this provides 
further evidence that the absence of DGAT1 in hepato-
cytes results specifically in the secretion of smaller VLDLs 
by the liver.
Effects of specific inhibition DGAT1 and DGAT2 on apoB 
secretion in HepG2 hepatocytes
The above data indicated that the absence of DGAT1 
from hepatocytes only affects the maturation and lipida-
tion of the nascent lipoprotein particles, and not the 
number of particles secreted. Because the latter depends 
on the initial lipidation of apoB during cotranslational 
translocation of the protein across the ER membrane, 
this step can potentially be supported by cytosol-facing 
(overt) DGAT1 (15, 23, 25) and/or by DGAT2, the cata-
lytic site of which is entirely cytosol-facing. Our previ-
ously published observations (25) showed that inhibition 
of DGAT1 affects primarily the utilization of preformed 
FAs for TAG synthesis and that, although DGAT2 also 
contributes substantially to this process, this enzyme is 
highly specialized for the incorporation of de novo syn-
thesized FAs and nascent DAG into cellular and secreted 
(VLDL) TAG (15, 23, 25). However, in those experiments 
we did not measure apoB secretion. Therefore, in order 
to address the question of whether apoB secretion is af-
fected when each of the two enzyme activities is inhibited 
in turn, we performed experiments with HepG2 cells in-
cubated with oleic acid (to stimulate lipoprotein secre-
tion) and with specific inhibitors of each of the two 
enzymes. The results in Fig. 6 show that neither inhibi-
tion of DGAT1 nor DGAT2 individually markedly sup-
pressed apoB secretion, although there were small 
decreases after inhibition of either enzyme. By contrast, 
ApoB secretion was almost totally inhibited when both 
enzymes were simultaneously inhibited (Fig. 6). This is 
consistent with the data (Fig. 4) indicating that, in vivo, 
even in the absence of DGAT1, DGAT2 by itself is able to 
support apoB secretion in smaller, TAG-poor particles.
Fig. 3. Expression of several lipogenic genes in the livers of WT 
and DGAT1-LKO mice. The levels of mRNA expression of several 
lipogenic enzymes were measured in the liver of WT and DGAT1-
LKO mice. There was a significant increase in GPAT1 mRNA rela-
tive to WT controls. * P < 0.05. There were no changes in the mRNA 
expression of other lipogenic genes. Values, in arbitrary units 
(A.U.), for each gene are expressed relative to the geomean of 
mRNA expression of two housekeeping genes, L19 and actin B, for 
five separate liver RNA preparations. ACC1, acetyl-CoA carboxylase 1; 
GPAT, glycerolphosphate acyltransferase; SCD1, steroyl-CoA decar-
boxylase 1.
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TAG content of the ER
In an attempt to demonstrate directly that deficiency of 
DGAT1 from hepatocytes in vivo interferes with the forma-
tion of ER TAG, we obtained electron micrographs of liver 
sections from control and DGAT1-LKO mice (Fig. 7). We 
also prepared purified microsomal fraction preparations 
and measured their TAG and protein content. When fed 
animals were used, no discernible differences were ob-
served between control and DGAT1-LKO mice with either 
technique (not shown). However, when FA availability to 
the livers was increased by fasting the animals for 16 h prior 
to sacrifice, we observed regions of smooth ER in control 
animals which were replete with TAG (Fig. 7A i, ii). These 
TAG-filled membranes were not observed in sections ob-
tained from DGAT1-LKO mouse livers (Fig. 7A iii, iv) in 
which the ER looked very similar to that in fed animals. 
Similarly, whereas upon 16 h fasting there was an increase 
in the TAG/protein ratio in purified endoplasmic reticular 
fractions of 23.00 ± 0.01 ng TAG/mg microsomal protein 
in control mouse microsomes, the increase in microsomes 
from fasted DGAT1-LKO mice was only 7.10 ± 0.01 ng 
TAG/mg protein (Fig. 7B). Consequently, the increase in 
TAG/protein ratio was significantly lower (P < 0.05) in mi-
crosomes from DGAT1-LKO mice than in control mice.
DISCUSSION
The main observation of this study is that the absence of 
DGAT1 from hepatocytes results in a markedly decreased 
diameter of VLDL particles, equivalent to the halving of 
their volume. This was accompanied by a decrease the 
TAG/apoB ratio of VLDL particles. These changes were 
achieved notwithstanding a similar overall content of TAG 
in the liver. This has implications for the understanding of 
the respective functions of DGAT1 and DGAT2 in the as-
sembly of mature VLDL particles secreted by the liver. The 
two enzymes catalyze the same, final reaction of TAG syn-
thesis, are coexpressed in hepatocytes and other cell 
types, and are partially redundant for the esterification of 
preformed FAs to TAG. However, DGAT2 has one special-
ized nonredundant function: in HepG2 cells (25), murine 
hepatocytes and mouse liver in vivo (28), and in mouse 
brown adipocytes (29), DGAT2 is specialized for the syn-
thesis of TAG from nascent DAG (containing newly synthe-
sized FAs) and de novo synthesized FAs (15). This is 
consistent with observations that DGAT2 associates with 
lipogenic enzymes (e.g., GPAT, Fpat1, and SCD1) in vari-
ous systems (15), and its expression is commonly induced 
together with that of lipogenic genes under the control of 
SREBP1c and/or ChREB (36, 37). In the liver (15, 25) and 
brown adipocytes (29), DGAT2 also contributes to the es-
terification of preformed FAs that arise either endoge-
nously through lipolysis or are derived from the circulation 
(either of dietary or adipose origins) to DAG, in hepato-
cytes and, to a greater extent, in brown adipocytes. How-
ever, it is DGAT1 [which is more active in the liver (23, 25)] 
that appears primarily to catalyze the reesterification of 
DAG and monoacylglycerol generated by TAG hydrolysis. 
It is noteworthy that in white adipocytes (white adipose tis-
sue), DGAT1 has the exclusive function of catalyzing the 
reesterification of FAs generated by endogenous TAG li-
polysis (38). Similarly, although DGAT2 mRNA expression 
is relatively high in cardiomyocytes, its specific inhibition 
does not affect esterification of oleate exogenously sup-
plied to the heart (30). These examples provide evidence 
for specialized roles of DGAT1 and DGAT2 in different cell 
types (15). Previous studies have quantified the effects of 
specific knockdown or overexpression of either DGAT1 or 
DGAT2 in liver and have shown that DGAT2 activity is pri-
marily associated with the development of hepatic steatosis 
(39–41), whereas overexpression of DGAT1 specifically in-
creases TAG secretion by the liver, and increased lipid ac-
cumulation in the smooth ER (31).
Rapid cycling between lipolysis and reesterification is a 
characteristic of hepatocyte TAG metabolism; in an earlier 
study we estimated that the rate of TAG-DAG cycling is 
more than an order of magnitude higher than the rate of 
FA utilization for TAG secretion in primary rat hepatocytes 
(12). DGAT1 is the primary contributor to this, but DGAT2, 
Fig. 4. Plasma concentration of TAG and apoB in DGAT1-LKO mice and controls after a 16 h fast. Mice 
were fasted for 16 h and then injected intraperitoneally with Triton WR-1339 to inhibit lipoprotein lipase ac-
tivity. After l h, they were anesthetized and bled; blood samples were collected using heparinized syringes, and 
the plasma fraction was obtained by centrifugation at 10,000 g for 5 min. The plasma samples were frozen, and 
the concentrations of TAG (A) and apoB (B) were measured as described in Methods. C: The TAG/apoB ratios 
were obtained for individual mice, and the ratio values were analyzed (paired t-test). Values are means  
(± SEM) for determinations on five separate mice for each condition. * P < 0.02 (values for DGAT1-LKO mice 
that are significantly different from those for WT controls).
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which is partially localized to the cytosolic LDs (27) also 
contributes to it (25). The function of this extensive hydro-
lysis-reesterification cycling may be related to the require-
ment to control the net rate of lipolysis of cytosolic LD-TAG 
to DAG, which is the immediate source of ER luminal non-
apoB-associated TAG used to lipidate the nascent lipopro-
tein particles to a secretion-competent size (15). VLDL-TAG 
secretion is related to hepatic TAG content (mostly within 
cytosolic LD) (9), and inhibition of lipolysis of this TAG 
pool results in a decrease in VLDL-TAG secretion (11).
A role for DAG in the effective transfer of the glyceride 
moiety across the ER membrane has been established (15) 
and is made possible when DAG is diverted away from re-
esterification on the cytosolic aspect of the membrane, 
crosses the ER membrane, and is reesterified on the ER 
luminal aspect. Previous studies (21, 23, 42–44) showed 
that a substantial proportion of DGAT1 activity of the hepa-
tocyte ER is not accessible to the cytosolic long-chain acyl-
CoA pool and can catalyze DAG esterification only if 
acyl-CoA is made accessible to the luminal aspect of the ER 
membrane. This trans-membrane system for synthesis of a 
pool of TAG that gives rise to non-apoB-associated TAG 
within the ER lumen has been reconstituted in vitro using 
ER vesicles (22) and is made possible by the dual topology 
of DGAT1 within the ER membrane (23). This is consistent 
with the previous observations that, in the absence of 
DGAT1, steatosis from preformed FAs is much diminished 
(35), presumably because this would require the activity of 
overt (cytosol-facing) DGAT1.
The current observations are also consistent with the 
proposed exclusive role of latent DGAT1 activity in the for-
mation of a pool of ER lumen TAG that is used for second-
step lipidation of nascent VLDLs. Thus, in DGAT1-LKO 
mice, the TAG content of the VLDL particles secreted by 
the liver is reduced approximately by half (Fig. 4) with a 
corresponding halving of the volume of the lipoprotein 
particles (Fig. 5), as would be anticipated from a require-
ment for ER lumen-facing (latent) DGAT1 activity for the 
formation of TAG in apoB-free LDs in the ER lumen. The 
difference between VLDL size in WT and DGAT1-LKO 
mice was specifically associated with the TAG content of 
the particles, as cholesterol and cholesteryl ester contents 
were unaffected. It is noteworthy that the size and TAG 
content of chylomicrons secreted by the intestine is also 
decreased in the absence of DGAT1 from enterocytes (45), 
in which the relationship between cytosolic TAG and TAG-
rich lipoprotein secretion appears to be similar to that in 
the liver (46).
The observation that plasma apoB concentrations after 
1 h Tyloxapol treatment was unaltered in DGAT1-LKO mice 
compared with control mice indicates that DGAT2 activ-
ity is largely sufficient, by itself, to meet the TAG synthesis 
requirements for the assembly of nascent (TAG-poor) 
Fig. 5. VLDL particles secreted by the liver of DGAT1-LKO mice 
are smaller than those secreted by WT animals. Plasma samples 
were prepared from either WT or DGAT1-LKO male mice fasted for 
6 h, and the VLDL fraction (d < 1.006) was prepared by step-gradi-
ent centrifugation, as described in Methods. A: Particle size deter-
mination was performed using DLS. Values are means (± SEM) for 
five separate determinations and are statistically significantly differ-
ent between DGAT1-LKO and WT (P < 0.01). B: The mean values 
are indicated by open squares and the upper and lower limits of the 
respective ranges by ×. Horizontal lines are medians; boxes show the 
interquartile range, and error bars show the SD.
Fig. 6. Incomplete redundancy in the ability of DGAT1 and 
DGAT2 to support ApoB secretion in HepG2 cells. HepG2 cells 
were incubated with oleic acid and glucose as substrates, as de-
scribed in Methods. ApoB secretion into the medium was measured 
(using ELISA) for a period of 4 h in the absence (control) or pres-
ence of specific inhibitors of DGAT1 (iDGATl) and/or DGAT2 
(iDGAT2) as indicated. The rate of ApoB secretion in control cells 
was 86.26 ng ApoB/h/mg cell protein. Values are expressed as a 
percentage of the rate observed for control cells in the same experi-
ment for n = 3 separate determinations. Each apoB measurement 
was performed in duplicate. * P < 0.02 (values that are significantly 
different from control).
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lipoprotein particles. This suggests that TAG synthesized 
by DGAT2 plays a central role in determining apoB secre-
tion (i.e., particle number). Conversely, DGAT2 alone can-
not maintain the size and TAG content of secreted VLDLs 
(this study), although, as expected from its role in esterify-
ing de novo synthesized FAs, previous studies have shown 
that it is fully capable of supporting hepatic steatosis (cyto-
solic LD-TAG synthesis) induced by an LXR agonist, i.e., 
through endogenous hepatic lipogenesis (35). In HepG2 
cells, both DGAT1 and DGAT2 inhibitors decreased apoB 
secretion but only moderately; these decreases were small 
compared with that observed when both activities were in-
hibited simultaneously.
As DGAT2 is largely responsible for the esterification of 
de novo FAs to nascent DAG (25, 28, 29), these observa-
tions are consistent with the central importance of FA syn-
thesis for hepatic secretion of TAG. This obligatory link 
between FA synthesis and VLDL-TAG secretion is a long-
established observation (47, 48). Therefore, the ability of 
DGAT2 to maintain particle number secretion but not full 
VLDL lipidation and maturation is consistent with previous 
observations that, although de novo synthesized FAs consti-
tute a small proportion of total TAG secreted (49–51), 
their incorporation is essential for TAG secretion (47, 48). 
Their contribution toward secreted VLDL-TAG is mark-
edly increased upon a high-carbohydrate (lipogenic) diet, 
when de novo FA synthesis is enhanced (51). Fig. 7 pres-
ents evidence that the TAG content of the ER is increased 
to a much greater extent in control than in DGAT1-LKO 
mice when exogenous FA supply is increased.
A graphical representation of the roles of DGAT1 and 
DGAT2 in the assembly of VLDL particles in WT and 
DGAT1-LKO mice, based on the current findings, is pre-
sented in Fig. 8.
The size of secreted VLDL, which primarily reflects their 
TAG content, is an important index of the pathogenicity 
of the dyslipidemia associated with the (pre)diabetic state 
Fig. 8. Proposed roles of DGAT1 and DGAT2 in the synthesis and 
secretion of VLDL TAG in WT (A) and DGAT1-LKO (B) mouse 
liver, based on the experimental observations. In WT mouse hepa-
tocytes, both overt DGAT1 (DGAT1o) and DGAT2 contribute to the 
(re)esterification of DAG with preformed (exogenous) FAs, al-
though DGATlo plays the major role. Conversely, DGAT2 is special-
ized for the esterification of de novo synthesized FAs (DNL) and 
nascent DAG. The TAG formed within the ER membrane is either 
used for the formation of cytosolic LDs or is associated with apoB 
during its cotranslational insertion through the ER membrane to 
form nascent lipoprotein particles. DAG equilibrates through the 
membrane to become the substrate for latent DGAT1 (DGAT1 L), 
which forms TAG destined for ER luminal LDs, and lipidation of 
nascent particles to form mature, TAG-rich VLDL, which is secreted. 
B: DGAT1 is absent (DGAT1-LKO), and no TAG enrichment (en-
largement) of the nascent lipoprotein particles occurs on the lumi-
nal aspect of the ER membrane. DGAT2-catalyzed TAG synthesis on 
the cytosolic aspect of the membrane is sufficient to sustain apoB 
secretion.
Fig. 7. Difference in the TAG content of microsomal lumen be-
tween fasted control and DGAT1-LKO mouse liver. Mice were fasted 
for 16 h to increase the supply of nonesterified FAs to the liver. Total 
liver TAG increased to the same extent in control and DGAT1-LKO 
mice (6.0 ± 0.5 and 5.3 ± 0.3 mg TAG/per mg liver in control and 
DGAT1-LKO livers, respectively. A: Electron micrographs of liver 
sections obtained from two separate control mice (i, ii) and two 
DGAT1-LKO mice (iii, iv) show the difference in TAG content of 
smooth ER (arrows). B: The difference in the increase in TAG con-
tent of purified microsomal fractions obtained from control and 
DGAT1-LKO mice is indicated. * P < 0.05.
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(52, 53). VLDL1-type particles are larger and more TAG-
rich, are increasingly secreted in diabetes (52, 53), and are 
more atherogenic (53, 54). Therefore, elucidation of the 
roles of DGAT1 and DGAT2 in the mechanism whereby 
the enlargement, through further lipidation of nascent 
VLDL particles with TAG, prior to their secretion is 
achieved is important, although it is appreciated that ob-
servations on DGAT2 in mice cannot invariably be extrapo-
lated to humans (55). Our studies show that DGAT1 is the 
enzyme responsible for determining VLDL particle size, 
whereas DGAT2 may be more important for determining 
the number of VLDL particles secreted, as it is capable of 
maintaining apoB secretion in the absence of DGAT1.
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